Under Friday’s final ruling anti-obesity medications for weight-loss will remain ineligible for Medicare coverage.

Novo Nordisk joined the many pharmaceutical companies pushing back on government-negotiated drug pricing in the United States.

The Trump administration has decided not to expand Medicare and Medicaid coverage for popular obesity drugs, blocking a Biden ...

U.S. Steel stock increased more than 16% in reaction to the decision to review the proposed merger with Nippon Steel for a second time.

The Centres for Medicare and Medicaid Services on Friday said that it did not move forward with a proposal put forward by the ...

In at least six letters published in the Seneca Courier-Tribune between January 2021 and March 2024, Hermesch airs his views ...

The Centers for Medicare and Medicaid Services did not explain why it was not finalizing the proposal, which the Biden ...

Long considered resistant to economic downturns, the pharmaceutical industry may face a greater challenge this time around as ...

The Trump administration did away with a Biden-era proposal to allow Medicare to start paying for weight loss drugs such as ...

Novo Nordisk said on Monday all eligible cash-paying customers in the United States can buy its weight-loss drug Wegovy at a ...

The proposal would have enabled more Americans to afford new medications in the GLP-1 class that have been shown to reduce ...